WCN25-3086 LONG-TERM RESULTS OF THE REDUCTION OF EXPOSURE TO CALCINEURIN INHIBITORS ASSOCIATED WITH mTOR INHIBITORS IN KIDNEY TRANSPLANTATION

WCN25-3086 LONG-TERM RESULTS OF THE REDUCTION OF EXPOSURE TO CALCINEURIN INHIBITORS ASSOCIATED WITH mTOR INHIBITORS IN KIDNEY TRANSPLANTATION

Saved in:

Bibliographic Details
Main Authors:	Pablo Raffaele, ADRIANA MARGARITA LITUMA ORELLANA, Pablo Klin, Cristian Costales Collaguazo, Pablo Bridoux, Alvaro Espinoza Guerrero, Rita Marcela Fortunato
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S246802492402970X
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-2410 LONG-TERM RESULTS OF THE REDUCTION OF EXPOSURE TO CALCINEURIN INHIBITORS ASSOCIATED WITH mTOR INHIBITORS IN KIDNEY TRANSPLANTATION
by: Pablo Raffaele, et al.
Published: (2025-02-01)

Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.
by: Aninda Basu, et al.
Published: (2011-01-01)

WCN24-2607 THROMBOTIC MICROANGIOPATHY AND KIDNEY TRANSPLANTATION (KT). A SINGLE CENTER EXPERIENCE
by: Alejandra Ines Espinoza, et al.
Published: (2024-04-01)

On the interchangeability of calcineurine inhibitors
by: K. E. Zatolochina, et al.
Published: (2018-02-01)

WCN25-3947 Experiences of performing ABO-incompatible kidney transplantation in Argentina
by: R. Marcela Fortunato, et al.
Published: (2025-02-01)

Genetic Evidence Supporting the Repurposing of mTOR Inhibitors for Reducing BMI
by: Ping Peng, et al.
Published: (2025-03-01)

Mechanisms of Nephrotoxic Action of Immunodepressants, Calcineurine Inhibitors
by: A. V. Nikitin
Published: (2020-05-01)

WCN24-1899 RECURRENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS IN KIDNEY TRANSPLANTATION
by: Adriana M. Lituma, et al.
Published: (2024-04-01)

Role of Calcineurin Inhibitors in the Management of Atopic Dermatitis in Children
by: Kamilla E. Efendieva, et al.
Published: (2023-12-01)

Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway
by: Adrish Sen, et al.
Published: (2025-01-01)

Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma—a tightrope walk
by: Nadine Muschel, et al.
Published: (2025-08-01)

Expression of concern: Compensatory increase of transglutaminase 2 is responsible for resistance to mTOR inhibitor treatment.
by: PLOS ONE Editors
Published: (2020-01-01)

Approaches to correction of immunosuppressive therapy in chronic nephrotoxicity of calcineurin inhibitors
by: E. S. Stolyarevich, et al.
Published: (2018-08-01)

In Silico Approach for Identification of PI3K/mTOR Dual Inhibitors for Multiple Myeloma Treatment
by: İlke Maşalacı, et al.
Published: (2023-06-01)

The role of calcineurin inhibitors in the progression of hepatocellular carcinoma after liver transplantation
by: O. D. Olisov, et al.
Published: (2022-09-01)

Efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus
by: N. Yu. Nikishina, et al.
Published: (2025-06-01)

A retrospective study of calcineurin inhibitors in the treatment of idiopathic membranous nephropathy
by: CUI Lin-lin, et al.
Published: (2015-01-01)

PHARMACOGENETICS OF CALCINEURIN INHIBITORS IN HEMATOPOIETIC CELL TRANSPLANTATION: A SYSTEMATIC REVIEW
by: LC Costa-Junior, et al.
Published: (2024-10-01)

Decreased calcineurin immunoreactivity in the postmortem brain of a patient with schizophrenia who had been prescribed the calcineurin inhibitor, tacrolimus, for leukemia
by: Wada A, et al.
Published: (2016-07-01)

AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake.
by: Ramachandran Rashmi, et al.
Published: (2014-01-01)

Factors associated with chronic calcineurin inhibitor nephrotoxicity in children with minimal-change disease
by: Bei Jin, et al.
Published: (2025-12-01)

Meta-analysis of calcineurin inhibitor vs.cyclophosphamide in the treatment of idiopathic membranous nephropathy
by: XIE Guang-liang, et al.
Published: (2015-01-01)

mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node
by: Laura Mantoan Ritter, et al.
Published: (2025-05-01)

Autophagy activation in breast cancer cells in vitro after the treatment with PI3K/AKT/mTOR inhibitors
by: D. D. Grigoreva, et al.
Published: (2022-12-01)

Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
by: Sofie Mohlin, et al.
Published: (2019-07-01)

The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing.
by: Rosario Diaz-Gonzalez, et al.
Published: (2011-08-01)

Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers
by: Ilham Kandoussi, et al.
Published: (2020-02-01)

Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders
by: Tanjala T. Gipson, et al.
Published: (2012-01-01)

Indications and Long-Term Outcomes of Using Mycophenolate Mofetil Monotherapy in Substitution for Calcineurin Inhibitors in Liver Transplantation
by: Carlos Jiménez-Romero, et al.
Published: (2025-02-01)

Analysis of early use of everolimus with low-dose calcineurin inhibitors in kidney transplant recipient
by: I. G. Kim, et al.
Published: (2019-10-01)

Prolonging calcineurin inhibitor therapy post kidney allograft failure: a prospective study
by: Rita Leal, et al.
Published: (2025-12-01)

Calcineurin‐inhibitor induced pain syndrome due to interaction with clarithromycin: A case report
by: Satoshi Inaba, et al.
Published: (2025-03-01)

Correction: Correction: AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake.
by: PLOS ONE Staff
Published: (2016-01-01)

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)
by: The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, et al.
Published: (2025-06-01)

WCN25-2809 TO STUDY CALCINEURIN INHIBITOR SPARING STRATEGIES IN PATIENTS WITH STAEROID RESISTANT AND STEROID DEPENDENT NEPHROTIC SYNDROME
by: Mahak Joshi, et al.
Published: (2025-02-01)

Long-term therapy of Kaposi’s sarcoma with the use of prospidium chloride and mTOR receptor inhibitors in а patient after kidney transplantation
by: E. V. Parabina, et al.
Published: (2020-09-01)

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
by: T. C. Schneider, et al.
Published: (2015-01-01)

WNT inhibitor SP5-mediated SERPING1 suppresses lung adenocarcinoma progression via TSC2/mTOR pathway
by: Yefeng Shen, et al.
Published: (2025-02-01)

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors
by: Anna Hernández‐Prat, et al.
Published: (2025-01-01)

High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line
by: Sijiao Wang, et al.
Published: (2024-03-01)